Lead Product(s) : TGX-007
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Trogenix
Deal Size : Undisclosed
Deal Type : Collaboration
Viralgen Collaborates with Trogenix to Advance AAV Gene Therapy for Glioblastoma
Details : The collaboration aims to advance the clinical development of Trogenix's rAAV gene therapy, TGX-007, which is being evaluated for glioblastoma.
Product Name : TGX-007
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 06, 2025
Lead Product(s) : TGX-007
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Trogenix
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Debio 0123,Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Collaboration
MEDSIR & Debiopharm Explore Synergy of Debio 0123 & Sacituzumab in Breast Cancer
Details : The collaboration aims to evaluate the safety and efficacy of Debio 0123, Debiopharm's investigational, potential best-in-class WEE1 inhibitor, together with Trodelvy (sacituzumab govitecan).
Product Name : Debio 0123
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 28, 2024
Lead Product(s) : Debio 0123,Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SRB21
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Debiopharm will boost its ADC oncology pipeline through SunRock’s antibody portfolio, including SRB21, an anti-HER3-HER2 bispecific, integrating Debiopharm’s Multilink™ & AbYlink™ technologies to create innovative antibody dr...
Product Name : SRB21
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
September 21, 2023
Lead Product(s) : SRB21
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : SRB22
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ellipses Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Ellipses has been granted global rights to develop and commercialise EP0017 and will assume the full cost and responsibility for the remaining pre-clinical and clinical development of the compound.
Product Name : EP0017
Product Type : Antibody
Upfront Cash : Undisclosed
May 25, 2022
Lead Product(s) : SRB22
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ellipses Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : AIT-102
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : AI Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)
Details : EC-8042 (redesignated AIT-102), is a targeted cancer therapy that inhibits the activity of SWI/SNF in certain tumors where SWI/SNF is mutated (such as Rhabdoid tumors) and in other tumors where SWI/SNF associates with oncogenic transcription factors.
Product Name : AIT-102
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 25, 2022
Lead Product(s) : AIT-102
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : AI Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : OMTX705
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $16.0 million
Deal Type : Financing
Details : These funds, together with Oncomatryx recurring revenues from its licensing agreements with international biopharmaceutical companies, will be used for the clinical development of additional ADCs of Oncomatryx tumour-microenvironment pipeline including O...
Product Name : OMTX705
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
April 22, 2022
Lead Product(s) : OMTX705
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $16.0 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Fund+
Deal Size : $33.6 million
Deal Type : Series A Financing
Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A Financing
Details : The financing will allow Ona Therapeutics to complete the pre-clinical development in a variety of tumor types and to move its lead candidate into first clinical studies in patients with metastatic cancer in 2023.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Fund+
Deal Size : $33.6 million
Deal Type : Series A Financing